Eric Easom - 18 Nov 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Issuer symbol
ANTX
Transactions as of
18 Nov 2024
Net transactions value
+$49,970
Form type
4
Filing time
18 Nov 2024, 20:51:42 UTC
Previous filing
29 Mar 2024
Next filing
28 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Purchase $49,970 +50,000 +4.9% $0.9994 1,065,766 18 Nov 2024 See Footnote F1
holding ANTX Common Stock 101,130 18 Nov 2024 Direct F2
holding ANTX Common Stock 97,058 18 Nov 2024 See Footnote F3
holding ANTX Common Stock 97,058 18 Nov 2024 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
F2 Includes 99,000 restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
F3 Consists of shares of Common Stock held by the C Easom Irrevocable Trust dated October 8, 2021.
F4 Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.